China channel feed – Endpoints News

China channel feed

China's Tasly Biopharma turns a development partner into an investor as it preps Hong Kong IPO

8 years ago

7 things you need to know now about raising biotech cash in China (Part 1)

8 years ago

Another IPO frenzy? Two US biotechs head to Hong Kong for a public market debut

8 years ago

Hong Kong exchange picks up steam with two biotech IPOs from Innovent, MicuRx

8 years ago

Sanofi gets serious in China with plans to hire 300 for $76M R&D site in Chengdu

8 years ago

Forget the biotech mega-round. Try the $200M-plus China 'ultra' on for size

8 years ago

C-Bridge hands Nuance Biotech $35M, opening doors to more China licensing deals

8 years ago

Latest ranking of top research institutions show China coming on strong — with significant implications for biotech

8 years ago

With an AstraZeneca cancer drug in one hand, $37M in the other, Shanghai's Alpha Bio zooms into a PhII study

8 years ago

High-profile Chinese investor Vincent Cheung plays a lead role in raising $100M round for a Boston start-up

8 years ago

A functional HIV cure? We have a long way to go, but Hong Kong investigators find a spotlight for their preclinical antibody

8 years ago

Bristol-Myers wins the frenzied race to a first approval for a PD-1/L1 checkpoint in China as regulators hustle up a quick OK

8 years ago

AI team at Insilico gets some major league backing from China as Alex Zhavoronkov builds global network

8 years ago

Sound familiar? China/US biotech hybrid lands rights to cancer drugs, cash and a team of development vets to launch Oncologie

8 years ago

Manufacturing experts at Hangzhou Just Biotherapeutics bank $35M for stealthy R&D in China and the US

8 years ago

Eyeing NDA for its diabetes drug, Hua Medicine knocks at HKEX's door with an IPO application

8 years ago

Prepping a drug launch, Zai Lab poaches AstraZeneca’s top cancer drug sales exec in China

8 years ago

With competition on its heels, Blueprint takes three cancer drugs to China

8 years ago

After sinking $300M into SF fund last year, Hong Kong conglomerate launches $100M arm in Shanghai

8 years ago

CRI report tracks explosive growth of cell therapies in the global pipeline, as China researchers muscle toward the front

8 years ago

Grail hauls in monster $300M round from Chinese investors amid rumors about Hong Kong IPO

8 years ago

China's CStone bags $260M Series B for ambitious I/O work, expanding its list of marquee investors

8 years ago

Set to be the first pre-revenue biotech to list in Hong Kong, Ascletis lays out priorities in IPO application

8 years ago

Ahead of Hong Kong listing changes, WuXi preps for a biotech boom with a new R&D center in Shanghai

8 years ago

First page Previous page 24 25 262728 29 30 Next page Last page